{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}],"title":"Progression-free survival"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"1 year post transplant relapse"},{"measurements":[{"groupId":"OG000","value":"3"}],"title":"2 year post transplant relapse"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"1- and 2-year Progression-free survival; Progression-free survival is defined as time from the date of autologous stem cell transplantation to progression, relapse and death, whichever comes first.","groups":[{"description":"Zydelig given orally at 150 mg twice daily continuously on 28-day cycles starting 30 to 120 days after autologous stem cell transplantation for patients with indolent or transformed indolent B-cell NHL, for up to 1 year maintenance duration. Dose withhold/modification is allowed according to tolerability/toxicity.\n\nZydelig: Zydelig given at 150mg continuously in 28-day cycles","id":"OG000","title":"Oral Zydelig 150 mg BID"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"1- and 2-year Progression-free survival","title":"Progression-free Survival at 1 and 2 Years After Autologous Stem Cell Transplantation.","type":"SECONDARY","unitOfMeasure":"Participants"}